CA-NETAPP
10.4.2024 19:01:45 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced an expansion of its partnership with Google Cloud to make it easier for organizations to leverage their data for generative AI (GenAI) and other hybrid cloud workloads. NetApp and Google Cloud are announcing the Flex service level for Google Cloud NetApp Volumes which supports storage volumes of nearly any size. NetApp is also releasing a preview of its GenAI toolkit reference architecture for retrieval-augmented generation (RAG) operations using Google Cloud Vertex AI platform.
More Flexible Data Storage Options for Google Cloud NetApp Volumes
Google Cloud and NetApp are announcing a new service level for NetApp Volumes called Flex that gives customers more granular control to adapt their storage and performance to match the exact needs of their cloud workloads.
“Increasing demand for data-intensive applications and insights has reinforced the need for a new approach to unified data storage that gives organizations the agility to move and store data wherever it is needed at any point in time,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “By extending our collaboration with Google Cloud, we’re delivering a flexible form factor that can be run on existing infrastructure across Google Cloud system without any tradeoffs to enterprise data management capabilities.”
With the addition of Flex, NetApp Volumes customers can choose from four service levels to leverage a fully managed file service built on NetApp ONTAPTM and operated by Google Cloud, including:
- Standard: highly available, general-purpose storage with advanced data management capabilities and 16MiB/sec per TiB of performance, which is recommended to support workloads such as file shares, virtual machines (VMs), and DevTest environments.
- Premium: highly available, high-performance storage with advanced data management capabilities and 64MiB/sec per TiB of performance, which is recommended for file shares, VMs, and databases.
- Extreme: highly available, low-latency, high-throughput storage with advanced data management capabilities and 128MiB/sec per TiB of performance, which is recommended for Online Transaction Processing (OLTP) high-performance databases and low-latency applications.
- Flex: highly available storage volumes with scalability from one GiB to 100TiB and up to one GiB/s of performance depending on the size of the underlying storage pool. This adaptable service level can support a wide variety of use cases, including AI.
“Google Cloud NetApp Volumes remains a critical component of every enterprise’s digital transformation strategy,” said Sameet Agarwal, GM/VP, Google Cloud Storage at Google Cloud. “Utilizing Google Cloud technologies, NetApp Volumes will power new capabilities that can improve how businesses operate and create real-world value for their organizations.”
The Flex service level will be generally available by Q2 2024 across 15 Google Cloud regions, expanding to the other Google Cloud regions by the end of 2024.
Unlocking Enterprise Data for Generative AI in Google Cloud
NetApp is also releasing a preview of its GenAI toolkit with support for NetApp Volumes. This offering, along with the accompanying reference architecture, speeds the implementation of RAG operations while enabling secure, consistent, and automated workflows that securely connect data stored in NetApp Volumes with Google Cloud Vertex AI platform. The result is a greater ability to generate unique, high-quality, and ultra-relevant insights and automations.
“As the intelligent data infrastructure company, we have unmatched capabilities to support data classification, tagging, mobility, and cloning for data wherever it lives so our customers can run efficient and secure AI data pipelines,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “Building on our partnership with Google Cloud to streamline RAG enables customers to tap into market-leading AI services and models to generate a unique competitive advantage.”
The NetApp GenAI toolkit helps optimize RAG processes with unique capabilities, including:
- Common data footprint everywhere: NetApp ONTAP allows customers to easily include data from any environment to power their RAG efforts with common operational processes while reducing risk, cost, and time to results.
- Automated classification and tagging: NetApp’s BlueXP classification service automatically tags data to support streamlined data cleansing for both the ingest and inferencing phases of the data pipeline, ensuring that the right data is used for queries and that sensitive data is not exposed to the model out of policy.
- Fast, scalable snapshots: ONTAP Snapshot delivers near-instant creation of space-efficient, in-place copies of vector stores and databases, allowing immediate roll back to a previous version if data is corrupted or forward if point-in-time analysis is needed.
- Real-time cloning at scale: ONTAP FlexClone technology can create instant clones of vector index stores to safely make uniquely relevant data instantly available for different queries for different users, without impacting the core production data.
“GenAI is a tidal wave of opportunity for the companies that can effectively apply their data to their industry,” said Miles Ward, CTO at SADA, An Insight Company. “At SADA we are fired up about pairing our extensive expertise with NetApp and Vertex AI to help customers accelerate their AI journeys. Why generate uninformed chats when you could generate unique, specific, relevant insights?”
The GenAI toolkit will be available as a public preview within the second half of 2024.
To learn more about the Flex service level for NetApp Volumes or the GenAI toolkit reference architecture for Vertex AI, visit the NetApp booth #1231 at the Google Cloud Next 2024 conference running from April 9-11 at Mandalay Bay in Las Vegas.
Additional Resources
- All Your Datasets are Welcome on Google Cloud NetApp Volumes. Did We Say No Trade-Offs?
- Introducing Google Cloud NetApp Volumes Flex Service Level
- Google Cloud NetApp Volumes
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410415954/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom